Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Kentucky takes stance on gabapentin to help reduce risk to public health

    by
    • Optum Workers' Comp
    | Jul 07, 2017
    Tag Icon
    FDA, DEA, Abuse Deterrent
    Kentucky has recently classified all gabapentin products as a Schedule V Controlled Substance to help reduce the risk to public health. This new state regulation, effective July 1, 2017, differs from federal regulations in that the state of Kentucky recognizes the abuse potential of gabapentin.


  • Endo has provided an update to the FDA

    by
    • Optum Workers' Comp
    | Jul 06, 2017
    Tag Icon
    Medication Recall, FDA
    UPDATE: Endo International plc has released a statement regarding the U.S. Food and Drug Administration’s (FDA) request in June 2017, to remove its reformulated Opana® ER (oxymorphone hydrochloride extended-release) from the market.


  • Louisiana Supreme Court settles pharmacy choice issue, employers retain the right to choose

    by
    | Jul 05, 2017
    Tag Icon
    Workers' Compensation
    Since the initiation of Sigler v. Rand in 2004, the Louisiana courts have been wrestling with the issue of who has the right to choose a pharmacy for an injured worker: the employer or the injured worker themselves. At the heart of the issue is Louisiana RS23:1203 which states, “the employer shall furnish all necessary drugs…” The lower courts in Louisiana have been split on whether or not this language in the statute grants authority to the employer to choose the pharmacy or if the employee is allowed to choose.


  • UPDATE: Florida takes regulatory action on compounds

    by
    • Optum Workers' Comp
    | Jun 30, 2017
    Tag Icon
    Workers' Compensation
    In response to a recent workcompcentral.com article regarding the pre-authorization of compounds over $1000 in Florida, we take this opportunity to re-release our blog post of May 11, 2017. Our original blog noted that the change in the pre-authorization applies to all compounded medications regardless of the billed amount. Pharmacies may submit compounded medications for pre-authorization and the claims administrator now has 10 days to respond to that request.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.